NYSTATIN- nystatin suspension
Kesin Pharma Corporation

NYSTATIN ORAL SUSPENSION, USP

Rx only

DESCRIPTION

Nystatin is an antimycotic polyene antibiotic obtained from *Streptomyces noursei*. Structural formula:



$C_{47}H_{75}NO_{17}$ MW = 926.13

Nystatin Oral Suspension, for oral administration, is cherry/mint flavored, containing 100,000 USP Nystatin Units per mL. Inactive ingredients: cherry flavor, dibasic sodium phosphate heptahydrate, disodium edetate, glycerin, methylparaben, monobasic sodium phosphate monohydrate, peppermint oil, propylparaben, sodium benzoate, sodium hexametaphosphate, and sucrose.

CLINICAL PHARMACOLOGY

Pharmacokinetics

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

Nystatin is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi. *Candida albicans* demonstrates no significant resistance to nystatin *in vitro*on repeated subculture in increasing *levels*o f nystatin; other *Candida species* become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible *Candida species* with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

General

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

Teratogenic Effects Category C

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

Pediatric Use

See **DOSAGE AND ADMINISTRATION.**

ADVERSE REACTIONS

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See **PRECAUTIONS: General**).

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

To report SUSPECTED ADVERSE REACTIONS, contact Kesin Pharma at 1-833-537-4679 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see **CLINICAL PHARMACOLOGY, Pharmacokinetics**).

DOSAGE AND ADMINISTRATION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of *Candida albicans*.

HOW SUPPLIED

Nystatin Oral Suspension, USP 100,000 USP Nystatin Units per mL, is available as a cherry-mint flavored, yellow, ready-to-use suspension, supplied in the following oral dosage forms:

NDC 81033-015-60: 60 mL bottle with a 1 mL calibrated dropper

NDC 81033-015-16: 16 oz (473 mL) bottle

Rx Only

SHAKE WELL BEFORE USE

SHAKE WELL BEFORE USE

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15° C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

AVOID FREEZING

Pharmacists: Dispense in a tight, light-resistant container as defined in the USP.

Distributed by:

Kesin Pharma

Oldsmar, FL 34677

Revised: 12/2025

PI-015B-V01

Nystatin 16 oz (473 mL)

Rx Only

NDC 81033- **015-**16

Nystatin Oral Suspension, USP

SHAKE WELL BEFORE USING



Nystatin 60 mL Bottle and Carton Labels

Rx Only

NDC 81033- **015**-60

Nystatin Oral Suspension, USP

SHAKE WELL BEFORE USING



Rx Only

NDC 81033- **015**-60

Nystatin Oral Suspension, USP

SHAKE WELL BEFORE USING
(Includes safe cap dropper)



NYSTATIN

nystatin suspension

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:81033-015(NDC:85742-013)
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**

NYSTATIN (UNII: BDF1O1C72E) (NYSTATIN - UNII:BDF1O1C72E)	NYSTATIN	100000 U in 1 mL

Inactive Ingredients

Ingredient Name	Strength
EDETATE DISODIUM (UNII: 7FLD91C86K)	
SODIUM BENZOATE (UNII: OJ245FE5EU)	
HEXASODIUM HEXAMETAPHOSPHATE (UNII: N40N91DW96)	
SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE (UNII: 70WT22SF4B)	
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)	
GLYCERIN (UNII: PDC6A3C0OX)	
METHYLPARABEN (UNII: A2I8C7HI9T)	
PROPYLPARABEN (UNII: Z8IX2SC1OH)	
SUCROSE (UNII: C151H8M554)	
PEPPERMINT OIL (UNII: AV092KU4JH)	

Product Characteristics

Color	yellow	**Score**	
Shape		**Size**	
Flavor	CHERRY (MINT)	**Imprint Code**	
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:81033-015-16	473 mL in 1 BOTTLE; Type 0: Not a Combination Product	06/30/2026	
2	NDC:81033-015-60	1 in 1 CARTON	08/31/2026	
2		60 mL in 1 BOTTLE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062832	08/14/2020	

Labeler - Kesin Pharma Corporation (117447816)

Revised: 6/2026 Kesin Pharma Corporation